World Courier expands clinical logistics
- Cencora’s World Courier is adding three U.S. transport stations, while rivals Marken and QuickSTAT keep widening cold-chain and clinical-trial logistics networks. - World Courier said the Denver, Indianapolis and San Diego sites lift its North American facility network to 17, adding cryogenic handling capacity. - Drugmakers are spending billions to secure supply chains as trial and injectable demand rises. (pharmexec.com)
World Courier is opening three new U.S. transport stations as drugmakers push for more cold-chain and clinical-trial logistics capacity. (cencora.com) Cencora said on December 19, 2023 that World Courier would add stations in Denver, Indianapolis and San Diego. The company said the expansion would raise its North American facility network to 17 sites. (cencora.com) The Indianapolis site is set up with liquid nitrogen tank and charging capabilities, giving World Courier more support for cryogenic shipments. Cencora also said World Courier recently launched a container freight station at New Hyde Park, New York, with U.S. Customs and Border Protection approval. (cencora.com) This is the business of moving medicines that can fail if they get too warm, too cold, or stuck in customs. Clinical trial materials, cell and gene therapies, and some injectables need tightly controlled storage, packaging and handoffs from factory to hospital or research site. (worldcourier.com) (cencora.com) Rivals are building around the same demand. Marken says its clinical depot network supports studies from Phase I through post-approval work, while its broader network is expanding storage and distribution coverage across regions. (marken.com 1) (marken.com 2) In February 2025, UPS folded Marken, MNX and Polar Speed into a single Marken, UPS Healthcare Precision Logistics brand. The company said the move combined healthcare and time-critical logistics capabilities under one network. (marken.com) QuickSTAT is pitching the same reliability to laboratories, hospitals and trial operators. The company says it handles time-critical healthcare shipments in more than 190 countries and supports temperature-controlled clinical-trial, biological-sample and organ transport. (quickstat.com 1) (quickstat.com 2) (quickstat.com 3) The demand signal is not limited to logistics providers. Eli Lilly said in February 2025 that it would invest up to $3.5 billion in a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania, part of a broader $50 billion U.S. manufacturing plan. (pharmexec.com) As more high-value medicines move in smaller, more sensitive batches, the supply-chain bottleneck shifts from ordinary warehousing to compliant storage and specialized transport. World Courier’s new stations are one piece of that larger buildout. (cencora.com) (pharmexec.com)
